489 related articles for article (PubMed ID: 25049327)
1. Outcomes of children with BCR-ABL1–like acute lymphoblastic leukemia treated with risk-directed therapy based on the levels of minimal residual disease.
Roberts KG; Pei D; Campana D; Payne-Turner D; Li Y; Cheng C; Sandlund JT; Jeha S; Easton J; Becksfort J; Zhang J; Coustan-Smith E; Raimondi SC; Leung WH; Relling MV; Evans WE; Downing JR; Mullighan CG; Pui CH
J Clin Oncol; 2014 Sep; 32(27):3012-20. PubMed ID: 25049327
[TBL] [Abstract][Full Text] [Related]
2. Predictive value of minimal residual disease in Philadelphia-chromosome-positive acute lymphoblastic leukemia treated with imatinib in the European intergroup study of post-induction treatment of Philadelphia-chromosome-positive acute lymphoblastic leukemia, based on immunoglobulin/T-cell receptor and BCR/ABL1 methodologies.
Cazzaniga G; De Lorenzo P; Alten J; Röttgers S; Hancock J; Saha V; Castor A; Madsen HO; Gandemer V; Cavé H; Leoni V; Köhler R; Ferrari GM; Bleckmann K; Pieters R; van der Velden V; Stary J; Zuna J; Escherich G; Stadt UZ; Aricò M; Conter V; Schrappe M; Valsecchi MG; Biondi A
Haematologica; 2018 Jan; 103(1):107-115. PubMed ID: 29079599
[TBL] [Abstract][Full Text] [Related]
3. Beneficial tyrosine kinase inhibitor therapy in a patient with relapsed BCR-ABL1-like acute lymphoblastic leukemia with CCDC88C-PDGFRB fusion.
Oya S; Morishige S; Ozawa H; Sasaki K; Semba Y; Yamasaki Y; Nakamura T; Aoyama K; Seki R; Mouri F; Osaki K; Miyamoto T; Maeda T; Nagafuji K
Int J Hematol; 2021 Feb; 113(2):285-289. PubMed ID: 32951102
[TBL] [Abstract][Full Text] [Related]
4. Tyrosine kinase fusion genes in pediatric BCR-ABL1-like acute lymphoblastic leukemia.
Boer JM; Steeghs EM; Marchante JR; Boeree A; Beaudoin JJ; Beverloo HB; Kuiper RP; Escherich G; van der Velden VH; van der Schoot CE; de Groot-Kruseman HA; Pieters R; den Boer ML
Oncotarget; 2017 Jan; 8(3):4618-4628. PubMed ID: 27894077
[TBL] [Abstract][Full Text] [Related]
5. High incidence of RAS pathway mutations among sentinel genetic lesions of Korean pediatric BCR-ABL1-like acute lymphoblastic leukemia.
Lee JW; Kim Y; Cho B; Kim S; Jang PS; Lee J; Cho H; Lee GD; Chung NG; Kim M
Cancer Med; 2020 Jul; 9(13):4632-4639. PubMed ID: 32378810
[TBL] [Abstract][Full Text] [Related]
6. Low incidence of ABL-class and JAK-STAT signaling pathway alterations in uniformly treated pediatric and adult B-cell acute lymphoblastic leukemia patients using MRD risk-directed approach - a population-based study.
Norvilas R; Dirse V; Semaskeviciene R; Mickeviciute O; Gineikiene E; Stoskus M; Vaitkeviciene G; Rascon J; Griskevicius L
BMC Cancer; 2021 Mar; 21(1):326. PubMed ID: 33781217
[TBL] [Abstract][Full Text] [Related]
7. Monitoring of childhood ALL using
Hovorkova L; Zaliova M; Venn NC; Bleckmann K; Trkova M; Potuckova E; Vaskova M; Linhartova J; Machova Polakova K; Fronkova E; Muskovic W; Giles JE; Shaw PJ; Cario G; Sutton R; Stary J; Trka J; Zuna J
Blood; 2017 May; 129(20):2771-2781. PubMed ID: 28331056
[TBL] [Abstract][Full Text] [Related]
8. Minimal residual disease in BCR::ABL1-positive acute lymphoblastic leukemia: different significance in typical ALL and in CML-like disease.
Zuna J; Hovorkova L; Krotka J; Koehrmann A; Bardini M; Winkowska L; Fronkova E; Alten J; Koehler R; Eckert C; Brizzolara L; Trkova M; Stuchly J; Zimmermann M; De Lorenzo P; Valsecchi MG; Conter V; Stary J; Schrappe M; Biondi A; Trka J; Zaliova M; Cazzaniga G; Cario G
Leukemia; 2022 Dec; 36(12):2793-2801. PubMed ID: 35933523
[TBL] [Abstract][Full Text] [Related]
9. Impact of tyrosine kinase inhibitors on minimal residual disease and outcome in childhood Philadelphia chromosome-positive acute lymphoblastic leukemia.
Jeha S; Coustan-Smith E; Pei D; Sandlund JT; Rubnitz JE; Howard SC; Inaba H; Bhojwani D; Metzger ML; Cheng C; Choi JK; Jacobsen J; Shurtleff SA; Raimondi S; Ribeiro RC; Pui CH; Campana D
Cancer; 2014 May; 120(10):1514-9. PubMed ID: 24501014
[TBL] [Abstract][Full Text] [Related]
10. BCR-ABL1-like acute lymphoblastic leukaemia: From bench to bedside.
Boer JM; den Boer ML
Eur J Cancer; 2017 Sep; 82():203-218. PubMed ID: 28709134
[TBL] [Abstract][Full Text] [Related]
11. T315I mutation exerts a dismal prognosis on adult BCR-ABL1-positive acute lymphoblastic leukemia, and salvage therapy with ponatinib or CAR-T cell and bridging to allogeneic hematopoietic stem cell transplantation can improve clinical outcomes.
Ting S; Mixue X; Lixia Z; Xueying L; Wanzhuo X; Xiujin Y
Ann Hematol; 2020 Apr; 99(4):829-834. PubMed ID: 32107574
[TBL] [Abstract][Full Text] [Related]
12. A novel targeted RNA-Seq panel identifies a subset of adult patients with acute lymphoblastic leukemia with BCR-ABL1-like characteristics.
Sánchez R; Ribera J; Morgades M; Ayala R; Onecha E; Ruiz-Heredia Y; Juárez-Rufián A; de Nicolás R; Sánchez-Pina J; Vives S; Zamora L; Mercadal S; Coll R; Cervera M; García O; Ribera JM; Martínez-López J
Blood Cancer J; 2020 Apr; 10(4):43. PubMed ID: 32332702
[TBL] [Abstract][Full Text] [Related]
13. BCR/ABL1-Like Acute Lymphoblastic Leukemia: From Diagnostic Approaches to Molecularly Targeted Therapy.
Płotka A; Lewandowski K
Acta Haematol; 2022; 145(2):122-131. PubMed ID: 34818644
[TBL] [Abstract][Full Text] [Related]
14. Independent prognostic value of BCR-ABL1-like signature and IKZF1 deletion, but not high CRLF2 expression, in children with B-cell precursor ALL.
van der Veer A; Waanders E; Pieters R; Willemse ME; Van Reijmersdal SV; Russell LJ; Harrison CJ; Evans WE; van der Velden VH; Hoogerbrugge PM; Van Leeuwen F; Escherich G; Horstmann MA; Mohammadi Khankahdani L; Rizopoulos D; De Groot-Kruseman HA; Sonneveld E; Kuiper RP; Den Boer ML
Blood; 2013 Oct; 122(15):2622-9. PubMed ID: 23974192
[TBL] [Abstract][Full Text] [Related]
15. Molecular genetic profile in BCR-ABL1 negative pediatric B-cell acute lymphoblastic leukemia can further refine outcome prediction in addition to that by end-induction minimal residual disease detection.
Gupta SK; Bakhshi S; Chopra A; Kamal VK
Leuk Lymphoma; 2018 Aug; 59(8):1899-1904. PubMed ID: 29199525
[TBL] [Abstract][Full Text] [Related]
16. Genomic landscape of B-other acute lymphoblastic leukemia in an adult retrospective cohort with a focus on
Hrabovsky S; Vrzalova Z; Stika J; Jelinkova H; Jarosova M; Navrkalova V; Martenek J; Folber F; Salek C; Horacek JM; Pospisilova S; Mayer J; Doubek M
Acta Oncol; 2021 Jun; 60(6):760-770. PubMed ID: 33750258
[TBL] [Abstract][Full Text] [Related]
17. Rapid identification of BCR/ABL1-like acute lymphoblastic leukaemia patients using a predictive statistical model based on quantitative real time-polymerase chain reaction: clinical, prognostic and therapeutic implications.
Chiaretti S; Messina M; Grammatico S; Piciocchi A; Fedullo AL; Di Giacomo F; Peragine N; Gianfelici V; Lauretti A; Bareja R; Martelli MP; Vignetti M; Apicella V; Vitale A; Li LS; Salek C; Elemento O; Inghirami G; Weinstock DM; Guarini A; Foà R
Br J Haematol; 2018 Jun; 181(5):642-652. PubMed ID: 29675955
[TBL] [Abstract][Full Text] [Related]
18.
Jain S; Abraham A
Arch Pathol Lab Med; 2020 Feb; 144(2):150-155. PubMed ID: 31644323
[TBL] [Abstract][Full Text] [Related]
19. BCR-ABL1-like B-lymphoblastic leukemia/lymphoma: Review of the entity and detection methodologies.
Conant JL; Czuchlewski DR
Int J Lab Hematol; 2019 May; 41 Suppl 1():126-130. PubMed ID: 31069976
[TBL] [Abstract][Full Text] [Related]
20. A subtype of childhood acute lymphoblastic leukaemia with poor treatment outcome: a genome-wide classification study.
Den Boer ML; van Slegtenhorst M; De Menezes RX; Cheok MH; Buijs-Gladdines JG; Peters ST; Van Zutven LJ; Beverloo HB; Van der Spek PJ; Escherich G; Horstmann MA; Janka-Schaub GE; Kamps WA; Evans WE; Pieters R
Lancet Oncol; 2009 Feb; 10(2):125-34. PubMed ID: 19138562
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
